Real-world management and patient perspectives on QOL with neuroendocrine tumours: An ANZ perspective

On 2 September 2020 a webinar was held titled “NET 2020” for Health Professionals and was sponsored by Novartis.

There were around 120 attendees at the event from across Australia which had a panel of NET Specialists providing information about current treatment options, an opportunity to take part in an in-depth discussion of a functional GEPNET patient case, a debate on the optimal clinical approach for non-functional GEPNET, and new data on quality of life issues affecting NET patients to improve supportive care. This article provides a summary of the presentations at the event which will be extremely interesting to the medical community.

Click the button below for full article.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Related Posts

NETs Q&A 2021

On Wednesday 9 June 2021 NeuroEndocrine Cancer Australia and Sydney Vital held a NET Patient Q&A session in the Auditorium at the Kolling Institute Royal